The company is expanding its preclinical work on acute respiratory syndrome to investigate whether its fibroblasts may help with deadly lung inflammation, vascular leakage, and tissue damage.
Researchers are exploring whether stem cell-derived extracellular vesicles could offer safer, targeted therapies for respiratory diseases, but technical hurdles remain.
The study will test whether induced pluripotent stem cells can help repair airway damage in people with COPD.
Researchers will test if umbilical cord stem cell infusions can safely reduce lung disease in extremely premature infants.
The Phase 2 trial RCT will evaluate adverse event and efficacy endpoints.
